India–EU FTA Paves Way for Expanded Healthcare Trade

On January 27, 2026, after years of negotiations, India and the European Union announced a landmark Free Trade Agreement.

- 

The move comes as both sides look to avoid deeper geopolitical friction by strengthening economic ties. More than 20 years in the making, the deal is widely seen as opening new doors for India's pharmaceutical and medical device sectors. Let's take a closer look at how it could impact these industries.

India and the European Union (EU) have announced the conclusion of negotiations for a Free Trade Agreement (FTA), marking a milestone in one of India's most strategic economic partnerships. Dubbed the 'mother of all deals,' the agreement is structured as a modern, rules-based trade framework designed to address current global trade challenges while enabling deeper market integration between the world's fourth and second largest economies.

The FTA unlocks access to the $572.3 billion EU pharmaceuticals and medical devices market, providing new opportunities for Indian manufacturers. The agreement is expected to support scaling of pharmaceutical production, employment generation, stronger MSME participation, and deeper integration into global supply chains. It reinforces India's position as a major supplier of medicines and medical technologies.

Key Highlights for Pharmaceuticals and Medical Devices

• Preferential market access to support growth in high-value segments

• Liberalised tariffs for key 'Made in India' medical devices

• Growth opportunities across inorganic and organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps, and detergents

• Capacity expansion and MSME cluster development

• Expansion across manufacturing hubs in Gujarat, Maharashtra, Karnataka, and Andhra Pradesh

• Strengthening of coastal export hubs to support export-led growth and employment